These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28532573)

  • 41. Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change.
    Ferreira RJO; Duarte C; Ndosi M; de Wit M; Gossec L; da Silva JAP
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):369-378. PubMed ID: 28544615
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of physician and patient global assessments over time in patients with rheumatoid arthritis: a retrospective analysis from the RADIUS cohort.
    Markenson JA; Koenig AS; Feng JY; Chaudhari S; Zack DJ; Collier D; Weaver A
    J Clin Rheumatol; 2013 Sep; 19(6):317-23. PubMed ID: 23965479
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Look beyond the disease activity score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis.
    Ton E; Bakker MF; Verstappen SM; Ter Borg EJ; van Albada-Kuipers IA; Schenk Y; van der Veen MJ; Bijlsma JW; Jacobs JW;
    J Rheumatol; 2012 Jan; 39(1):22-7. PubMed ID: 22002014
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Standardized grip strength as an outcome measure in early rheumatoid arthritis.
    Sheehy C; Gaffney K; Mukhtyar C
    Scand J Rheumatol; 2013; 42(4):289-93. PubMed ID: 23311733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice?
    Soubrier M; Zerkak D; Gossec L; Ayral X; Roux C; Dougados M
    J Rheumatol; 2006 Jul; 33(7):1243-6. PubMed ID: 16622906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical performance of rheumatoid arthritis impact of disease score: a real-life evidence from the multicenter nationwide registry BioStaR.
    Melikoglu MA; Ataman S; Bodur H; Cay HF; Capkin E; Akgul O; Cevik R; Gogus F; Kamanli A; Yurdakul FG; Gurer G; Yagci I; Rezvani A; Duruoz MT; Sunar I
    Rheumatol Int; 2021 Nov; 41(11):1971-1978. PubMed ID: 34559275
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient-derived joint counts are a potential alternative for determining Disease Activity Score.
    Kavanaugh A; Lee SJ; Weng HH; Chon Y; Huang XY; Lin SL
    J Rheumatol; 2010 May; 37(5):1035-41. PubMed ID: 20156946
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A; Poil AR; Hammoudeh M
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. No clear association between ultrasound remission and health status in rheumatoid arthritis patients in clinical remission.
    van der Ven M; Kuijper TM; Gerards AH; Tchetverikov I; Weel AE; van Zeben J; Hazes JM; Luime JJ
    Rheumatology (Oxford); 2017 Aug; 56(8):1276-1281. PubMed ID: 28407127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Number of active joints, not diagnosis, is the primary determinant of function and performance in early synovitis.
    Gerber LH; Furst G; Yarboro C; el-Gabalawy H
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S65-70. PubMed ID: 14969053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A patient-derived disease activity score can substitute for a physician-derived disease activity score in clinical research.
    Houssien DA; Stucki G; Scott DL
    Rheumatology (Oxford); 1999 Jan; 38(1):48-52. PubMed ID: 10334682
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Remission in rheumatoid arthritis by different criteria does not converge over the inflammatory markers.
    Chandrashekara S; Priyanka BU
    Int J Rheum Dis; 2013 Jun; 16(3):291-6. PubMed ID: 23981750
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study.
    Perrotta FM; De Socio A; Scriffignano S; Lubrano E
    Clin Rheumatol; 2018 Jun; 37(6):1449-1455. PubMed ID: 29468339
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort.
    Kristensen LE; Bliddal H; Christensen R; Karlsson JA; Gülfe A; Saxne T; Geborek P
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):173-9. PubMed ID: 23982986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can routine clinical measures predict ultrasound-determined synovitis and remission in rheumatoid arthritis patients?
    Nemoto T; Ogasawara M; Matsuki Y; Murayama G; Yamada Y; Sugisaki N; Ando S; Minowa K; Kon T; Tada K; Matsushita M; Yamaji K; Tamura N; Takasaki Y
    Clin Exp Rheumatol; 2014; 32(1):54-60. PubMed ID: 24144300
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis.
    Chandrashekara S; Rajendran A; Bai Jaganath A; Krishnamurthy R
    Reumatismo; 2015 Dec; 67(3):109-15. PubMed ID: 26876190
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. a 5-year followup study.
    Mäkinen H; Kautiainen H; Hannonen P; Sokka T
    J Rheumatol; 2005 May; 32(5):796-800. PubMed ID: 15868611
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study.
    Kubo S; Saito K; Hirata S; Fukuyo S; Yamaoka K; Sawamukai N; Nawata M; Iwata S; Mizuno Y; Tanaka Y
    Mod Rheumatol; 2014 Jan; 24(1):42-51. PubMed ID: 24261758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.
    Choy T; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
    Rheumatology (Oxford); 2014 Mar; 53(3):482-90. PubMed ID: 24241035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.